Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Alzheimers Dement ; 17(12): 1976-1987, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-33984181

RESUMO

INTRODUCTION: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development. METHODS: A targeted, stable isotope, quantitative mass spectrometry-based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline. RESULTS: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i.e., CN vs. MCI participants; AD pathology positive vs. negative defined by phosphorylated tau181/amyloid beta1-42 ratio; and clinical progressors vs. non-progressors). The rate of change of NPTX2 also significantly correlated with declining cognition. DISCUSSION: CSF NPTX2 concentration is a strong prognostic biomarker candidate of accelerated cognitive decline with potential use as a therapeutic target.


Assuntos
Doença de Alzheimer , Biomarcadores/líquido cefalorraquidiano , Proteína C-Reativa/líquido cefalorraquidiano , Disfunção Cognitiva , Proteínas do Tecido Nervoso/líquido cefalorraquidiano , Proteômica , Idoso , Doença de Alzheimer/líquido cefalorraquidiano , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/líquido cefalorraquidiano , Disfunção Cognitiva/líquido cefalorraquidiano , Disfunção Cognitiva/patologia , Humanos , Estudos Longitudinais , Espectrometria de Massas , Fosforilação , Proteínas tau/líquido cefalorraquidiano
2.
Neurobiol Dis ; 22(2): 404-20, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16439141

RESUMO

Sporadic Parkinson's disease (PD) is most likely caused by a combination of environmental exposures and genetic susceptibilities, although there are rare monogenic forms of the disease. Mitochondrial impairment at complex I, oxidative stress, alpha-synuclein aggregation, and dysfunctional protein degradation, have been implicated in PD pathogenesis, but how they are related to each other is unclear. To further evaluated PD pathogenesis here, we used in vivo and in vitro models of chronic low-grade complex I inhibition with the pesticide rotenone. Chronic rotenone exposure in vivo caused oxidative modification of DJ-1, accumulation of alpha-synuclein, and proteasomal impairment. Interestingly, the effects become more regionally restricted such that systemic complex I inhibition eventually results in highly selective degeneration of the nigrostriatal pathway. DJ-1 modifications, alpha-synuclein accumulation, and proteasomal dysfunction were also seen in vitro and these effects could be prevented with alpha-tocopherol. Thus, chronic exposure to a pesticide and mitochondrial toxin brings into play three systems, DJ-1, alpha-synuclein, and the ubiquitin-proteasome system, and implies that mitochondrial dysfunction and oxidative stress link environmental and genetic forms of the disease.


Assuntos
Degeneração Neural/induzido quimicamente , Proteínas Oncogênicas/efeitos dos fármacos , Transtornos Parkinsonianos/induzido quimicamente , Complexo de Endopeptidases do Proteassoma/efeitos dos fármacos , Rotenona/toxicidade , Ubiquitina/efeitos dos fármacos , alfa-Sinucleína/efeitos dos fármacos , Animais , Linhagem Celular Tumoral , Modelos Animais de Doenças , Complexo I de Transporte de Elétrons/efeitos dos fármacos , Complexo I de Transporte de Elétrons/fisiologia , Metabolismo Energético/efeitos dos fármacos , Metabolismo Energético/fisiologia , Humanos , Inseticidas/toxicidade , Masculino , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Degeneração Neural/metabolismo , Degeneração Neural/fisiopatologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Proteínas Oncogênicas/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Estresse Oxidativo/fisiologia , Transtornos Parkinsonianos/metabolismo , Transtornos Parkinsonianos/fisiopatologia , Peroxirredoxinas , Complexo de Endopeptidases do Proteassoma/metabolismo , Proteína Desglicase DJ-1 , Ratos , Ratos Endogâmicos Lew , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Substância Negra/efeitos dos fármacos , Substância Negra/metabolismo , Substância Negra/fisiopatologia , Ubiquitina/metabolismo , alfa-Sinucleína/metabolismo
3.
Brain Res Mol Brain Res ; 134(1): 76-83, 2005 Mar 24.
Artigo em Inglês | MEDLINE | ID: mdl-15790532

RESUMO

Mutations in the DJ-1 gene are associated with recessive, early onset Parkinson's disease (PD). We reported previously that one of the point mutations, L166P, destabilizes the protein and thus produces an effective knockout of the gene. Here, we have expanded this analysis to include a series of mutations and polymorphisms identified throughout the gene. The M26I point mutation was also unstable, although the effect was not as dramatic as with L166P. Protein levels were rescued in part, but not completely, by proteasome inhibition. Other variants, such as R98Q, were generally stable. We noted that M26I and L166P are both in helical regions near the dimer interface. However, M26I retains the ability to dimerize. We also examined the subcellular localization of DJ-1 and found that most mutations were similar to the wild-type (wt) protein in that a few cells showed mitochondrial staining. However, in all cases, the proportion of cells with mitochondrial DJ-1 staining was increased in oxidative conditions, suggesting that oxidation promotes the mitochondrial localization of DJ-1.


Assuntos
Acetilcisteína/análogos & derivados , Proteínas Oncogênicas/genética , Mutação Puntual , Polimorfismo Genético , Acetilcisteína/farmacologia , Cloreto de Amônio/farmacologia , Análise de Variância , Animais , Western Blotting/métodos , Linhagem Celular Tumoral , Cicloeximida/farmacologia , Inibidores de Cisteína Proteinase/farmacologia , Dimerização , Imunofluorescência/métodos , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação da Expressão Gênica/fisiologia , Proteínas de Fluorescência Verde/metabolismo , Humanos , Imunoprecipitação/métodos , Peptídeos e Proteínas de Sinalização Intracelular , Camundongos , Modelos Moleculares , Neuroblastoma , Proteínas Oncogênicas/química , Proteína Desglicase DJ-1 , Inibidores da Síntese de Proteínas/farmacologia , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Frações Subcelulares/metabolismo , Fatores de Tempo , Transfecção/métodos
4.
Proc Natl Acad Sci U S A ; 101(24): 9103-8, 2004 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-15181200

RESUMO

Loss-of-function DJ-1 mutations can cause early-onset Parkinson's disease. The function of DJ-1 is unknown, but an acidic isoform accumulates after oxidative stress, leading to the suggestion that DJ-1 is protective under these conditions. We addressed whether this represents a posttranslational modification at cysteine residues by systematically mutating cysteine residues in human DJ-1. WT or C53A DJ-1 was readily oxidized in cultured cells, generating a pI 5.8 isoform, but an artificial C106A mutant was not. We observed a cysteine-sulfinic acid at C106 in crystalline DJ-1 but no modification of C53 or C46. Oxidation of DJ-1 was promoted by the crystallization procedure. In addition, oxidation-induced mitochondrial relocalization of DJ-1 and protection against cell death were abrogated in C106A but not C53A or C46A. We suggest that DJ-1 protects against neuronal death, and that this is signaled by acidification of the key cysteine residue, C106.


Assuntos
Cisteína/análogos & derivados , Cisteína/metabolismo , Mitocôndrias/metabolismo , Fármacos Neuroprotetores/metabolismo , Proteínas Oncogênicas/metabolismo , 1-Metil-4-fenilpiridínio/toxicidade , Substituição de Aminoácidos , Linhagem Celular Tumoral , Cisteína/química , Cisteína/genética , Humanos , Membranas Intracelulares/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular , Modelos Moleculares , Neurotransmissores , Proteínas Oncogênicas/química , Proteínas Oncogênicas/genética , Oxirredução , Estresse Oxidativo , Proteína Desglicase DJ-1 , Isoformas de Proteínas , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Eletricidade Estática , Transfecção
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...